| Business Summary | | DepoMed,
Inc.
is
a
development-stage
company
engaged
in
the
development
of
new
and
proprietary
oral
drug
delivery
technologies.
The
Company
has
developed
two
types
of
oral
drug
delivery
systems,
the
Gastric
Retention
System
(the
GR
System)
and
the
Reduced
Irritation
System
(the
RI
System).
The
GR
System
is
designed
to
be
retained
in
the
stomach
for
an
extended
period
of
time
while
it
delivers
the
incorporated
drug
or
drugs,
and
the
RI
System
is
designed
to
reduce
the
gastrointestinal
irritation
that
is
a
side
effect
of
many
orally
administered
drugs.
In
addition,
the
DepoMed
Systems
are
designed
to
provide
continuous,
controlled
delivery
of
an
incorporated
drug. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | DepoMed,
Inc.
is
a
development
stage
company
engaged
in
the
development
of
new
and
proprietary
oral
drug
delivery
technologies
designed
to
reduce
gastrointestinal
irritation
and
provide
continuous,
controlled
delivery
of
an
incorporated
drug.
For
the
six
months
ended
6/30/01,
revenues
rose
53%
to
$1.5
million.
Net
loss
applicable
to
Common
totaled
$8.6
million,
up
from
$4.2
million.
Results
reflect
new
collaborative
agreements,
offset
by
higher
clinical
trial
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Fara, Ph.D., 58 Chairman,
Pres, CEO | $451K | John Hamilton, 56 VP-
Fin., CFO | 226K | John Shell, 47 VP
- Operations, Director | 205K | Bret Berner, Ph.D., 48 VP-
Product Devel. | 205K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|